Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Oct 2017)
Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE‐ACS Study
Abstract
BackgroundAngina has important implications for patients’ quality of life and healthcare utilization. Angina management after acute myocardial infarction (MI) treated with percutaneous coronary intervention (PCI) is unknown. Methods and ResultsTRANSLATE‐ACS (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) was a longitudinal study of MI patients treated with percutaneous coronary intervention at 233 US hospitals from 2010 to 2012. Among patients with self‐reported angina at 6 weeks post‐MI, we described patterns of angina and antianginal medication use through 1 year postdischarge. Of 10 870 percutaneous coronary intervention–treated MI patients, 3190 (29.3%) reported angina symptoms at 6 weeks post‐MI; of these, 658 (20.6%) had daily/weekly angina while 2532 (79.4%) had monthly angina. Among patients with 6‐week angina, 2936 (92.0%) received β‐blockers during the 1 year post‐MI, yet only 743 (23.3%) were treated with other antianginal medications. At 1 year, 1056 patients (33.1%) with 6‐week angina reported persistent angina symptoms. Of these, only 31.2% had been prescribed non–β‐blocker antianginal medications at any time in the past year. Among patients undergoing revascularization during follow‐up, only 25.9% were on ≥1 non–β‐blocker anti‐anginal medication at the time of the procedure. ConclusionsAngina is present in one third of percutaneous coronary intervention–treated MI patients as early as 6 weeks after discharge, and many of these patients have persistent angina at 1 year. Non–β‐blocker antianginal medications are infrequently used in these patients, even among those with persistent angina and those undergoing revascularization.
Keywords
